Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$0.08 USD
+0.02 (22.82%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $0.08 0.00 (-2.20%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Adaptimmune Therapeutics PLC's return on equity, or ROE, is -163.73% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that ADAP has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ADAP 0.08 +0.02(22.82%)
Will ADAP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ADAP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ADAP
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Crossed Above 20 Day Moving Average appears for ADAP after 18.93% move
Is ADAP ready to move higher? Pocket Pivot shows up after rallying 10.89%
Is ADAP set to breakout? NR7 shows up after sinking 0.59%